Esperion Therapeutics, Inc. (ESPR)
USD 1.09
(10.77%)
USD 1.09
(10.77%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 660.79 Million USD | 15.58% |
| 2022 | 571.71 Million USD | -1.18% |
| 2021 | 578.53 Million USD | 28.74% |
| 2020 | 449.39 Million USD | 131.05% |
| 2019 | 194.49 Million USD | 202.33% |
| 2018 | 64.33 Million USD | 94.1% |
| 2017 | 33.14 Million USD | 99.53% |
| 2016 | 16.61 Million USD | 99.82% |
| 2015 | 8.31 Million USD | -15.09% |
| 2014 | 9.79 Million USD | 132.96% |
| 2013 | 4.2 Million USD | -82.99% |
| 2012 | 24.7 Million USD | 199.91% |
| 2011 | 8.23 Million USD | 0.0% |
| 2002 | 12.66 Million USD | 6.94% |
| 2001 | 11.84 Million USD | 16.26% |
| 2000 | 10.18 Million USD | 96.48% |
| 1999 | 5.18 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 696.53 Million USD | 4.37% |
| 2024 Q1 | 667.35 Million USD | 0.99% |
| 2023 Q3 | 631.3 Million USD | 4.07% |
| 2023 FY | 660.79 Million USD | 15.58% |
| 2023 Q1 | 581.48 Million USD | 1.71% |
| 2023 Q4 | 660.79 Million USD | 4.67% |
| 2023 Q2 | 606.6 Million USD | 4.32% |
| 2022 Q1 | 591.89 Million USD | 2.31% |
| 2022 FY | 571.71 Million USD | -1.18% |
| 2022 Q2 | 595.67 Million USD | 0.64% |
| 2022 Q3 | 606.92 Million USD | 1.89% |
| 2022 Q4 | 571.71 Million USD | -5.8% |
| 2021 Q3 | 587.96 Million USD | 0.55% |
| 2021 Q4 | 578.53 Million USD | -1.6% |
| 2021 Q2 | 584.77 Million USD | 6.71% |
| 2021 FY | 578.53 Million USD | 28.74% |
| 2021 Q1 | 548 Million USD | 21.94% |
| 2020 Q2 | 244.86 Million USD | 6.51% |
| 2020 Q1 | 229.88 Million USD | 18.2% |
| 2020 Q3 | 242 Million USD | -1.17% |
| 2020 Q4 | 449.39 Million USD | 85.69% |
| 2020 FY | 449.39 Million USD | 131.05% |
| 2019 FY | 194.49 Million USD | 202.33% |
| 2019 Q2 | 179.48 Million USD | 191.97% |
| 2019 Q4 | 194.49 Million USD | 4.14% |
| 2019 Q3 | 186.75 Million USD | 4.06% |
| 2019 Q1 | 61.47 Million USD | -4.45% |
| 2018 Q4 | 64.33 Million USD | 52.14% |
| 2018 FY | 64.33 Million USD | 94.1% |
| 2018 Q3 | 42.28 Million USD | 20.94% |
| 2018 Q2 | 34.96 Million USD | 16.36% |
| 2018 Q1 | 30.04 Million USD | -9.34% |
| 2017 Q2 | 31.13 Million USD | 40.31% |
| 2017 FY | 33.14 Million USD | 99.53% |
| 2017 Q4 | 33.14 Million USD | -5.29% |
| 2017 Q3 | 34.99 Million USD | 12.4% |
| 2017 Q1 | 22.19 Million USD | 33.59% |
| 2016 FY | 16.61 Million USD | 99.82% |
| 2016 Q1 | 8.27 Million USD | -0.45% |
| 2016 Q2 | 9.5 Million USD | 14.86% |
| 2016 Q3 | 9.61 Million USD | 1.1% |
| 2016 Q4 | 16.61 Million USD | 72.83% |
| 2015 Q4 | 8.31 Million USD | -16.13% |
| 2015 FY | 8.31 Million USD | -15.09% |
| 2015 Q1 | 10.79 Million USD | 10.26% |
| 2015 Q2 | 10.5 Million USD | -2.71% |
| 2015 Q3 | 9.91 Million USD | -5.62% |
| 2014 Q4 | 9.79 Million USD | -5.02% |
| 2014 Q2 | 10.37 Million USD | 225.53% |
| 2014 FY | 9.79 Million USD | 132.96% |
| 2014 Q1 | 3.18 Million USD | -24.14% |
| 2014 Q3 | 10.3 Million USD | -0.68% |
| 2013 Q1 | 2.52 Million USD | -89.79% |
| 2013 FY | 4.2 Million USD | -82.99% |
| 2013 Q4 | 4.2 Million USD | 25.71% |
| 2013 Q3 | 3.34 Million USD | -49.69% |
| 2013 Q2 | 6.64 Million USD | 163.54% |
| 2012 FY | 24.7 Million USD | 199.91% |
| 2012 Q4 | 24.7 Million USD | 0.0% |
| 2011 FY | 8.23 Million USD | 0.0% |
| 2003 Q1 | 12.67 Million USD | 0.12% |
| 2003 Q2 | 14.48 Million USD | 14.2% |
| 2003 Q3 | 14.37 Million USD | -0.75% |
| 2002 Q3 | 12.02 Million USD | -4.06% |
| 2002 Q2 | 12.53 Million USD | -1.99% |
| 2002 Q4 | 12.66 Million USD | 5.31% |
| 2002 FY | 12.66 Million USD | 6.94% |
| 2002 Q1 | 12.78 Million USD | 8.0% |
| 2001 Q1 | 9.97 Million USD | -2.1% |
| 2001 Q2 | 11.87 Million USD | 19.12% |
| 2001 Q3 | 12.2 Million USD | 2.75% |
| 2001 Q4 | 11.84 Million USD | -2.98% |
| 2001 FY | 11.84 Million USD | 16.26% |
| 2000 Q3 | 10.02 Million USD | 36.42% |
| 2000 Q1 | 5.4 Million USD | 0.0% |
| 2000 FY | 10.18 Million USD | 96.48% |
| 2000 Q2 | 7.34 Million USD | 35.93% |
| 2000 Q4 | 10.18 Million USD | 1.66% |
| 1999 FY | 5.18 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | -40.095% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | -303.154% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 30.287% |
| Cosmos Health Inc. | 30.25 Million USD | -2084.247% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -7682.67% |
| Cronos Group Inc. | 43.73 Million USD | -1410.858% |
| Incannex Healthcare Limited | 5.83 Million USD | -11234.305% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -1264.0% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | -200.632% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -300926.823% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -10662.753% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -10662.753% |
| SCYNEXIS, Inc. | 55.45 Million USD | -1091.686% |
| Safety Shot Inc | 3.89 Million USD | -16877.968% |
| Theratechnologies Inc. | 98.63 Million USD | -569.907% |
| Alpha Teknova, Inc. | 38.55 Million USD | -1614.067% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -4704.232% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 6.172% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -7446.711% |
| Dynavax Technologies Corporation | 375.02 Million USD | -76.199% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 19.156% |
| Radius Health, Inc. | 804.29 Million USD | 17.842% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -7085.147% |
| Alvotech | 1.88 Billion USD | 64.9% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | -382.783% |
| SIGA Technologies, Inc. | 57.97 Million USD | -1039.739% |
| Shineco, Inc. | 47.6 Million USD | -1288.165% |
| Silver Spike Investment Corp. | 3 Million USD | -21854.389% |
| Journey Medical Corporation | 56.49 Million USD | -1069.561% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -3000.005% |
| Embecta Corp. | 2.03 Billion USD | 67.546% |
| Harrow Health, Inc. | 241.75 Million USD | -173.333% |
| Procaps Group, S.A. | 462.06 Million USD | -43.008% |
| Biofrontera Inc. | 23.13 Million USD | -2755.741% |
| DURECT Corporation | 30.4 Million USD | -2073.222% |
| PainReform Ltd. | 2.69 Million USD | -24455.556% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -35.558% |
| OptiNose, Inc. | 194.33 Million USD | -240.026% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -3049.9% |
| Organogenesis Holdings Inc. | 181.36 Million USD | -264.349% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -1158.259% |
| ProPhase Labs, Inc. | 42.54 Million USD | -1453.192% |
| Phibro Animal Health Corporation | 725.54 Million USD | 8.925% |
| Procaps Group S.A. | 462.06 Million USD | -43.008% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -4612.523% |
| Viatris Inc. | 27.21 Billion USD | 97.572% |
| Rockwell Medical, Inc. | 30.88 Million USD | -2039.725% |
| Aytu BioPharma, Inc. | 90.37 Million USD | -631.132% |
| Tilray Brands, Inc. | 892.11 Million USD | 25.93% |
| PetIQ, Inc. | 645.22 Million USD | -2.412% |
| Talphera, Inc. | 6.29 Million USD | -10405.405% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 35.179% |
| Alimera Sciences, Inc. | 107.35 Million USD | -515.524% |
| Assertio Holdings, Inc. | 148.41 Million USD | -345.228% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -34752.437% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | -281.107% |
| Hempacco Co., Inc. | 18.82 Million USD | -3410.657% |
| Alvotech | 1.88 Billion USD | 64.9% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 20.888% |
| Kamada Ltd. | 109.96 Million USD | -500.891% |
| Currenc Group, Inc. | 177.67 Million USD | -271.908% |
| Indivior PLC | 1.95 Billion USD | 66.135% |
| Evoke Pharma, Inc. | 9.64 Million USD | -6748.925% |
| Flora Growth Corp. | 17.22 Million USD | -3736.895% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -7682.67% |
| Evolus, Inc. | 209.68 Million USD | -215.132% |
| HUTCHMED (China) Limited | 536.38 Million USD | -23.193% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 24.351% |
| Akanda Corp. | 12.66 Million USD | -5115.85% |